Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data - PubMed (original) (raw)
Meta-Analysis
. 2001 Jul 17;135(2):73-87.
doi: 10.7326/0003-4819-135-2-200107170-00007.
C H Schmid, M Landa, I Giatras, R Toto, G Remuzzi, G Maschio, B M Brenner, A Kamper, P Zucchelli, G Becker, A Himmelmann, K Bannister, P Landais, S Shahinfar, P E de Jong, D de Zeeuw, J Lau, A S Levey
Affiliations
- PMID: 11453706
- DOI: 10.7326/0003-4819-135-2-200107170-00007
Meta-Analysis
Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data
T H Jafar et al. Ann Intern Med. 2001.
Erratum in
- Ann Intern Med 2002 Aug 20;137(4):299
Abstract
Purpose: To examine the efficacy of ACE inhibitors for treatment of nondiabetic renal disease.
Data sources: 11 randomized, controlled trials comparing the efficacy of antihypertensive regimens including ACE inhibitors to the efficacy of regimens without ACE inhibitors in predominantly nondiabetic renal disease.
Study selection: Studies were identified by searching the MEDLINE database for English-language studies evaluating the effects of ACE inhibitors on renal disease in humans between May 1977 (when ACE inhibitors were approved for trials in humans) and September 1997.
Data extraction: Data on 1860 nondiabetic patients were analyzed.
Data synthesis: Mean duration of follow-up was 2.2 years. Patients in the ACE inhibitor group had a greater mean decrease in systolic and diastolic blood pressure (4.5 mm Hg [95% CI, 3.0 to 6.1 mm Hg]) and 2.3 mm Hg [CI, 1.4 to 3.2 mm Hg], respectively) and urinary protein excretion (0.46 g/d [CI, 0.33 to 0.59 g/d]). After adjustment for patient and study characteristics at baseline and changes in systolic blood pressure and urinary protein excretion during follow-up, relative risks in the ACE inhibitor group were 0.69 (CI, 0.51 to 0.94) for end-stage renal disease and 0.70 (CI, 0.55 to 0.88) for the combined outcome of doubling of the baseline serum creatinine concentration or end-stage renal disease. Patients with greater urinary protein excretion at baseline benefited more from ACE inhibitor therapy (P = 0.03 and P = 0.001, respectively), but the data were inconclusive as to whether the benefit extended to patients with baseline urinary protein excretion less than 0.5 g/d.
Conclusion: Antihypertensive regimens that include ACE inhibitors are more effective than regimens without ACE inhibitors in slowing the progression of nondiabetic renal disease. The beneficial effect of ACE inhibitors is mediated by factors in addition to decreasing blood pressure and urinary protein excretion and is greater in patients with proteinuria. Angiotensin-converting inhibitors are indicated for treatment of nondiabetic patients with chronic renal disease and proteinuria and, possibly, those without proteinuria.
Comment in
- The effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a pooled analysis of individual-patient data from 11 randomized, controlled trials.
Schrier RW, Estacio RO. Schrier RW, et al. Ann Intern Med. 2001 Jul 17;135(2):138-9. doi: 10.7326/0003-4819-135-2-200107170-00015. Ann Intern Med. 2001. PMID: 11453714 No abstract available. - Review: angiotensin-converting enzyme inhibitors reduce the progression of nondiabetic renal disease.
Berns JS. Berns JS. ACP J Club. 2002 Jan-Feb;136(1):12. ACP J Club. 2002. PMID: 11829553 No abstract available.
Similar articles
- Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis.
Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS; AIPRD Study Group. Jafar TH, et al. Ann Intern Med. 2003 Aug 19;139(4):244-52. doi: 10.7326/0003-4819-139-4-200308190-00006. Ann Intern Med. 2003. PMID: 12965979 - Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease.
Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, de Jong PE, de Zeeuw D, Shahinfar S, Ruggenenti P, Remuzzi G, Levey AS; AIPRD Study Group. Angiotensin-Converting Enzymne Inhibition and Progression of Renal Disease. Jafar TH, et al. Kidney Int. 2001 Sep;60(3):1131-40. doi: 10.1046/j.1523-1755.2001.0600031131.x. Kidney Int. 2001. PMID: 11532109 Clinical Trial. - Renal protection and antihypertensive drugs: current status.
Salvetti A, Mattei P, Sudano I. Salvetti A, et al. Drugs. 1999 May;57(5):665-93. doi: 10.2165/00003495-199957050-00002. Drugs. 1999. PMID: 10353294 Review. - Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR. Weir MR. Clin Ther. 2007 Sep;29(9):1803-24. doi: 10.1016/j.clinthera.2007.09.019. Clin Ther. 2007. PMID: 18035185 Review.
Cited by
- Effect of blood pressure control on the risk of proteinuria during bevacizumab treatment in patients with colorectal cancer: a single-center retrospective cohort study.
Nihei S, Asaka J, Yaegashi M, Asahi K, Kudo K. Nihei S, et al. J Pharm Health Care Sci. 2024 Aug 23;10(1):51. doi: 10.1186/s40780-024-00372-8. J Pharm Health Care Sci. 2024. PMID: 39180119 Free PMC article. - Screening for chronic kidney disease: change of perspective and novel developments.
van Mil D, Kieneker LM, Heerspink HJL, Gansevoort RT. van Mil D, et al. Curr Opin Nephrol Hypertens. 2024 Nov 1;33(6):583-592. doi: 10.1097/MNH.0000000000001016. Epub 2024 Aug 13. Curr Opin Nephrol Hypertens. 2024. PMID: 39137037 Free PMC article. Review. - SGLT-2 inhibitors: new horizons for rheumatologists.
Chakrabarti K, McCune WJ. Chakrabarti K, et al. Curr Opin Rheumatol. 2024 Sep 1;36(5):351-359. doi: 10.1097/BOR.0000000000001030. Epub 2024 Jul 24. Curr Opin Rheumatol. 2024. PMID: 39007236 Free PMC article. Review. - Drugs in Development to Treat IgA Nephropathy.
Del Vecchio L, Allinovi M, Comolli S, Peiti S, Rimoldi C, Locatelli F. Del Vecchio L, et al. Drugs. 2024 May;84(5):503-525. doi: 10.1007/s40265-024-02036-1. Epub 2024 May 23. Drugs. 2024. PMID: 38777962 Review. - Framework of Guidelines for Management of CKD in Asia.
Pollock C, Moon JY, Ngoc Ha LP, Gojaseni P, Ching CH, Gomez L, Chan TM, Wu MJ, Yeo SC, Nugroho P, Bhalla AK. Pollock C, et al. Kidney Int Rep. 2023 Dec 22;9(4):752-790. doi: 10.1016/j.ekir.2023.12.010. eCollection 2024 Apr. Kidney Int Rep. 2023. PMID: 38765566 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous